NEW YORK, May 29, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), McKesson Corporation (NYSE: MCK), AmerisourceBergen Corporation (NYSE: ABC), Horizon Pharma, Inc. (NASDAQ: HZNP) and Sanofi SA (NYSE: SNY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3079-100free.
Johnson & Johnson Analyst Notes
On May 19, 2014, Johnson & Johnson announced that Ethicon Endo-Surgery, Inc. (Ethicon), part of the Johnson & Johnson Family of Companies, launched the HARMONIC ACE+7 Shears with Advanced Hemostasis (HARMONIC ACE+7), the first purely ultrasonic device with a 7mm sealing indication. Ethicon noted that the product combines the precision and multi-functionality of HARMONIC with reliable large vessel sealing, which the Company emphasized as non-existent in any other product, representing a breakthrough in ultrasonic energy technology. "The HARMONIC ACE+7 represents a breakthrough in ultrasonic technology that now enhances surgeon choice. Surgeons no longer need to trade off precision and multi-functionality for sealing strength. It may in some cases also reduce the need for additional devices, such as clips, improving procedure efficiency," said Tom O'Brien, Vice President of Energy Global Strategic Marketing at Ethicon. The full analyst notes on Johnson & Johnson are available to download free of charge at:
McKesson Corporation Analyst Notes
On May 21, 2014, McKesson Corporation (McKesson) announced that its Executive Vice President and CFO, James Beer, will be presenting at the Goldman Sachs 35th Annual Global Healthcare Conference in Rancho Palos Verdes. Beer is scheduled to present on June 11, 2014 at 2:00 p.m. PT. The full analyst notes on McKesson are available to download free of charge at:
AmerisourceBergen Corporation Analyst Notes
On May 22, 2014, AmerisourceBergen Corporation (AmerisourceBergen) announced the closing of its public offering of $600 million aggregate principal amount 1.150% Senior Notes due 2017 and $500 million aggregate principal amount of its 3.400% Senior Notes due 2024. In addition, the Company also informed that it intends to redeem any and all outstanding aggregate principal amounts of its 5 ⅞% Senior Notes due 2015 on June 23, 2014. The full analyst notes on AmerisourceBergen are available to download free of charge at:
Horizon Pharma, Inc. Analyst Notes
On May 23, 2014, Horizon Pharma, Inc. (Horizon Pharma) announced that the Compensation Committee of its Board of Directors has approved the grant of inducement stock options to purchase an aggregate of 21,000 shares of common stock to Horizon Pharma's six new employees in accordance with NASDAQ Listing Rule 5635(c)(4). According to the Company, each stock option has an exercise price per share equivalent to $13.46 and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter. The Company also explained that each stock option has a 10-year term. The full analyst notes on Horizon Pharma are available to download free of charge at:
Sanofi SA Analyst Notes
On May 5, 2014, the vaccines division of Sanofi SA (Sanofi), Sanofi Pasteur, announced that it has received prequalification status from the World Health Organization (WHO) for its pediatric pentavalent vaccine Shan5, developed and manufactured by its affiliate Shantha Biotechnics in India. The Company informed that following the recommendation of WHO's auditors, Shan5 vaccine was qualified for purchase by United Nations agencies, mainly UNICEF. "Shan5 is the first product that puts together the best of Shantha and Sanofi Pasteur's assets and talents," said Olivier Charmeil, President and CEO of Sanofi Pasteur. "Today, a significant number of babies born every year do not have access to modern vaccination programs. By delivering large supplies of high-quality and affordable vaccines to emerging and low-income countries, Shantha will be contributing to filling this gap for the benefits of babies and their parents." The full analyst notes on Sanofi are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review